Immunic, Inc. (Nasdaq: IMUX),
a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838 s potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, ITT), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, PP).
Investegate announcements from Immunic, Inc., Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
DGAP-News: Immun .
DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
vom 18.02.2021, 12:30 Uhr
Bild: pixabay.com
DGAP-News: Immunic, Inc. / Key word(s): Study results
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
18.02.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
- Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -
Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo.
On holiday, about to run the marathon that the surgery made possible.
Christmas Day 2016. I have recovered from the liver transplant in May that I needed to stop my primary sclerosing cholangitis, a degenerative liver disease that, without a transplant, can cause cirrhosis and eventually death.
Now I face repeated hospitalizations because of my other health problem, ulcerative colitis, a bowel disease, since September of that year. Iâm yellow, breathless and staggering around in a restaurant with my family, who are all clearly convinced that Iâm going to collapse at any moment. Ulcerative colitis has blighted my life for nearly 25 years, and I think itâs finally killing me.